Address
997 Lenox Drive
Lawrenceville, NJ 08648
United States of America (the)
Phone
609 896 9100
Website
Sector
Healthcare
Industry
Biotechnology
Employees
25
First IPO Date
March 01, 1999
| Name | Title | Pay | Year Born |
| Stacy R. Lindborg | President, Chief Executive Officer & Director | 925,349 | 1971 |
| Douglas V. Faller | Chief Medical Officer | 559,462 | 1953 |
| Michael H. Tardugno | Executive Chairman | 571,225 | 1951 |
| Jeffrey W. Church | Interim Chief Financial Officer | 798,171 | 1957 |
| Kristin Longobardi | Senior Vice President of Strategic Operations | 0 | N/A |
| Susan Mary Eylward | General Counsel & Corporate Secretary | 0 | 1980 |
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.